FDA Approval - Search News

FDA approves leucovorin for rare genetic condition

FDA approves new use of synthetic vitamin B9 — but not for autism symptoms

The Food and Drug Administration on Tuesday announced a new approved use for the drug leucovorin, a synthetic form of vitamin B9 that the Trump administration has touted as a treatment for autism symp...

· 2d

FDA approves generic drug for a rare genetic condition, but not for autism

· 2d · on MSN

US FDA approves leucovorin for rare genetic disorder causing autism-like symptoms

· 1d

FDA won’t endorse Leucovorin for autism

The FDA expanded the use of prescription drug Leucovorin, but said it won’t recommend it for autism.

· 1d

FDA OKs drug for rare brain disorder

· 2d

FDA approves leucovorin for rare genetic condition, but not for autism

FDA, Josh Hawley

Digest more

· 1d · on MSN

Hawley introduces bill to strip FDA approval from 'inherently dangerous' abortion pill

FIRST ON FOX: Sen. Josh Hawley, R-Mo., is introducing a new bill to strip FDA approval from the popular abortion pill mifepristone.

IJR · 1d

Hawley Introduces Bill Forcing Trump Admin To Protect Unborn From Chemical Abortion

· 1d · on MSN

Josh Hawley introduces bill to revoke FDA approval of mifepristone for abortions

GlobalData on MSN

FDA approves GSK’s Wellcovorin for cerebral folate deficiency

FDA worked with GSK to update Wellcovorin labelling for safe, effective use in adult and paediatric CFD-FOLR1 patients.

Healio

FDA approves Johnson & Johnson’s Tecnis PureSee IOL

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release from Johnson & Johnson.

FDA considers closing approval loophole

U. S. Food and Drug Administrator Marty Makary called on the agency to close a loophole for companies often used to secure product approval.

GlobalData on MSN

BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

Johnson & Johnson (J&J) has announced the US Food and Drug Administration (FDA) approval for the combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults with relapsed or refractory multiple myeloma (r/r MM).